中外健康文摘
中外健康文摘
중외건강문적
WORLD HEALTH DIGEST
2013年
26期
88-89
,共2页
冉亨勇%蒲军%彭秀兰(通讯作者)
冉亨勇%蒲軍%彭秀蘭(通訊作者)
염형용%포군%팽수란(통신작자)
鼻咽癌%西妥昔单抗%同步放化疗
鼻嚥癌%西妥昔單抗%同步放化療
비인암%서타석단항%동보방화료
nasopharyngeal cancer%Cetuximab%chemoradiation
目的观察西妥昔单抗联合同步放化疗治疗中晚期鼻咽癌的近期疗效。方法将50例中晚期鼻咽癌患者随机分为两组：同步放化疗组（chemoradiation group，RT+CT组）25例，西妥昔单抗联合同步放化疗治疗组（chemoradiation + cetuximab group，RT+CT+C组）25例，两组的放化疗方法相同。RT+CT+C组在放化疗开始前西妥昔单抗首剂400mg/m2静脉输液，其后250mg/m2，均为每周1次，共7周。结果近期临床疗效：RT+CT+C组的完全缓解（complete remission,CR）率68.0%（17/25），部分缓解（partial remission,PR）率28.0%﹙7/25﹚，稳定（no change,NC）率4.0%﹙1/25﹚，有效率（CR+ PR）96.0%；RT+CT组的CR率44.0%﹙11/25﹚，PR率32.0%﹙8/25﹚，NC率24.0%﹙6/25﹚，有效率（CR+ PR）76.0%。RT+CT+C组的CR及有效率均高于RT+CT组，差异有显著性﹙p<0.05﹚。结论西妥昔单抗联合同步放化疗可提高中晚期鼻咽癌的近期疗效。
目的觀察西妥昔單抗聯閤同步放化療治療中晚期鼻嚥癌的近期療效。方法將50例中晚期鼻嚥癌患者隨機分為兩組：同步放化療組（chemoradiation group，RT+CT組）25例，西妥昔單抗聯閤同步放化療治療組（chemoradiation + cetuximab group，RT+CT+C組）25例，兩組的放化療方法相同。RT+CT+C組在放化療開始前西妥昔單抗首劑400mg/m2靜脈輸液，其後250mg/m2，均為每週1次，共7週。結果近期臨床療效：RT+CT+C組的完全緩解（complete remission,CR）率68.0%（17/25），部分緩解（partial remission,PR）率28.0%﹙7/25﹚，穩定（no change,NC）率4.0%﹙1/25﹚，有效率（CR+ PR）96.0%；RT+CT組的CR率44.0%﹙11/25﹚，PR率32.0%﹙8/25﹚，NC率24.0%﹙6/25﹚，有效率（CR+ PR）76.0%。RT+CT+C組的CR及有效率均高于RT+CT組，差異有顯著性﹙p<0.05﹚。結論西妥昔單抗聯閤同步放化療可提高中晚期鼻嚥癌的近期療效。
목적관찰서타석단항연합동보방화료치료중만기비인암적근기료효。방법장50례중만기비인암환자수궤분위량조：동보방화료조（chemoradiation group，RT+CT조）25례，서타석단항연합동보방화료치료조（chemoradiation + cetuximab group，RT+CT+C조）25례，량조적방화료방법상동。RT+CT+C조재방화료개시전서타석단항수제400mg/m2정맥수액，기후250mg/m2，균위매주1차，공7주。결과근기림상료효：RT+CT+C조적완전완해（complete remission,CR）솔68.0%（17/25），부분완해（partial remission,PR）솔28.0%﹙7/25﹚，은정（no change,NC）솔4.0%﹙1/25﹚，유효솔（CR+ PR）96.0%；RT+CT조적CR솔44.0%﹙11/25﹚，PR솔32.0%﹙8/25﹚，NC솔24.0%﹙6/25﹚，유효솔（CR+ PR）76.0%。RT+CT+C조적CR급유효솔균고우RT+CT조，차이유현저성﹙p<0.05﹚。결론서타석단항연합동보방화료가제고중만기비인암적근기료효。
Objective:To observe the recent efficacy of cetuximab combined with chemoradiation for advanced nasopharyngeal cancer. Methods: Fifty cases with nasopharyngeal cancer (UICCⅡb to Ⅳa) were divided randomly into two groups: chemoradiation group(RT+CT group) were 25 cases,Cetuximab combined with chemoradiation group(RT+CT+C group) were 25 cases. The chemoradiation methods of RT+CT group were the same as those of RT+CT+C group. The individuals in RT+CT+C groups were accepted intravenous infusion of cetuximab (400mg/m2 one week before radiation, and then 250mg/m2 per week)were given concurrently,The total times of intravenous infusion were seven weeks. Results:The recent efficacy of RT+CT+C group was as follows:the complete remission(CR) rate was 68.0%(17/25),the partial remission(PR) rate was 28.0%(7/25),the no change(NC)rate was 4.0%(1/25) and the effective rate(CR+PR) was 96.0%. The recent efficacy of RT+CT group was as follows:The CR rate was 44.0%(11/25), the PR rate was 32.0% (8/25) ,the NC rate was 24.0% (6/25) and the effective rate(CR+PR) was 76.0%. The effective rate and complete remission rate of RT+CT+C group was higher than those of RT+CT group. There was significant statistical difference between the two groups. Conclusion: Cetuximab combined with chemoradiation can improve the recent efficacy of advanced nasopharyngeal cancer.
